Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015;Immuntherapie von Kopf-Hals-Karzinomen: Highlights des ASCO-Kongresses 2015

HNO

Volumn 63, Issue 9, 2015, Pages 612-619

  Laban, S ^a   Doescher, J ^a   Schuler, P J ^a   Bullinger, L ^a   Brunner, C ^a   Veit, J A ^a   Hoffmann, T K ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Head and neck squamous cell carcinoma; Immune checkpoint modulation; Immunomodulation; Immunotherapy; Programmed cell death 1

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

CARCINOMA, SQUAMOUS CELL; EVIDENCE BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84941082495     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-015-0054-1     Document Type: Article

References (26)

1. Boisselier P, Graff-Cailleaud P, Sire C et al (2015) Double blind multicenter phase III GORTEC trial evaluating the efficacy of oral immune modulating formulae therapy during adjuvant radiochemotherapy in head and neck squamous cell carcinoma (HNSCC). ASCO Meet Abstr 33:6066
2. Cohen EEW, Machiels J-PH, Harrington KJ et al (2015) KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. ASCO Meet Abstr 33:TPS6084
3. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
4. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567
5. Heusinkveld M, Welters MJ, Van Poelgeest MI et al (2011) The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 128:379–389
6. Hodi FS, O’day SJ, Mcdermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
7. Hoffmann TK, Arsov C, Schirlau K et al (2006) T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118:1984–1991
8. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
9. Leidner RS, Patel SP, Fury MG et al (2015) A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). ASCO Meet Abstr 33:TPS6083
10. Miles B, Gnjatic S, Donovan M et al (2015) Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer. ASCO Meet Abstr 33:TPS6088
11. Nauts HC, Swift WE, Coley BL (1946) The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6:205–216
12. Parikh F, Duluc D, Imai N et al (2014) Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 74(24):7205–7216
13. Powell SF, Liu SV, Sukari A et al (2015) KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. ASCO Meet Abstr 33:TPS3094
14. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
15. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
16. Saloura V, Zuo Z, Khattri A et al (2015) Patterns of CD8+ T-cell infiltration and immune escape mechanisms in head and neck cancer. ASCO Meet Abstr 33:6078
17. Segal NH, Ou S-HI, Balmanoukian AS et al (2015) Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO Meet Abstr 33:3011
18. Seiwert TY, Burtness B, Weiss J et al (2015) Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. ASCO Meet Abstr 33:6017
19. Seiwert TY, Burtness B, Weiss J et al (2014) A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meet Abstr 32:6011
20. Seiwert TY, Haddad RI, Gupta S et al (2015) Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. ASCO Meet Abstr 33:LBA6008
21. Siu LL, Papadopoulos KP, Tsai FY-C et al (2015) Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). ASCO Meet Abstr 33:TPS3090
22. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
23. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21(Suppl 7):vii252–261
24. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133
25. Zandberg DP, Jarkowski A, Emeribe UA et al (2015) A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530). ASCO Meet Abstr 33:TPS6086
26. Zuo Z, Saloura V, Kohrt HE et al (2015) Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel candidate biomarkers for checkpoint blockade therapy. ASCO Meet Abstr 33:6079